Sanofi American Depositary Shares (Each representing one-half of one ordinary share) (SNY)
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 12, 2025 | $2.20 | 2025-05-09 | 2025-05-09 |
| June 6, 2024 | $2.04 | 2024-05-09 | 2024-05-10 |
| June 23, 2023 | $1.90 | 2023-05-30 | 2023-05-31 |
| May 31, 2022 | $1.75 | 2022-05-04 | 2022-05-05 |
| May 26, 2021 | $1.93 | 2021-05-03 | 2021-05-04 |
Dividends Summary
- Sanofi American Depositary Shares (Each representing one-half of one ordinary share) has issued 18 dividend payments over the past 17 years
- The most recent dividend was paid 100 days ago, on June 12, 2025
- The highest dividend payed out to investors during this period was $2.195331 per share
- The average dividend paid during this period was $1.76 per share.
Company News
Sanofi shared positive phase 2a study results for brivekimig, a potential treatment for hidradenitis suppurativa. The drug showed clinically meaningful improvements, with 67% of patients achieving HiSCR50 compared to 37% on placebo after 16 weeks.
The immune thrombocytopenic purpura (ITP) market is expected to grow at a 1.9% CAGR from 2025-2034, with Sanofi's WAYRILZ approval marking a significant shift in treatment options and sparking competition among pharmaceutical companies developing novel therapies.
MacroGenics reported Q2 2025 financial results with revenue of $22.2 million, missing analyst expectations. The company is focusing on its research-stage pipeline and strategic partnerships while managing costs after exiting its previous marketed product.
Regeneron Pharmaceuticals reported better-than-expected Q2 results, driven by growth in Eylea HD, Dupixent, and Libtayo. However, Eylea sales declined due to increased competition. The company's pipeline progress was mixed, with a delay in the FDA decision for linvoseltamab and a three-month extension for the Dupixent COPD indication.
JMP Securities initiated coverage on Inhibrx Inc. with a Market Perform rating following the acquisition of INBRX-101 by Sanofi. The newly formed Inhibrx Biosciences has a strong financial foundation, but faces challenges with negative profitability metrics.